Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 250mg;   - powder for injection - 250 mg - active: flucloxacillin sodium monohydrate 250mg  

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 500mg;   - powder for injection - 500 mg - active: flucloxacillin sodium monohydrate 500mg  

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - flucloxacillin sodium monohydrate, quantity: 281.89 mg - capsule - excipient ingredients: methyl hydroxybenzoate; titanium dioxide; indigo carmine; gelatin; magnesium stearate; propyl hydroxybenzoate; purified water; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - flucloxacillin sodium monohydrate, quantity: 563.78 mg - capsule - excipient ingredients: indigo carmine; methyl hydroxybenzoate; propyl hydroxybenzoate; gelatin; magnesium stearate; titanium dioxide; purified water; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

США - англійська - NLM (National Library of Medicine)

a-s medication solutions - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility  testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. dicloxacillin sodium is contraindicated in persons who have shown hypersensitivity to any of the penicillins or any component of the formulations.

США - англійська - NLM (National Library of Medicine)

a-s medication solutions - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility plate testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal in

Ізраїль - англійська - Ministry of Health

a.l. medi-market ltd. - cloxacillin as sodium - powder for solution for inj/inf - cloxacillin as sodium 500 mg/vial - cloxacillin - cloxacillin is indicated for the treatment of sensitive staphylococcal infections:respiratory infections, otorhinolaryngologic infections, renal infections, urogenital infections, neuro-meningeal infections, bone and joint infections, endocarditis, and treatment of skin infections caused by sensitive staphylococci and/or streptococci.cloxacillin is also indicated as preventive treatment of postoperative infections in neurosurgery.

Ізраїль - англійська - Ministry of Health

a.l. medi-market ltd. - cloxacillin as sodium - powder for solution for inj/inf - cloxacillin as sodium 1000 mg/vial - cloxacillin - cloxacillin is indicated for the treatment of sensitive staphylococcal infections: respiratory infections, otorhinolaryngologic infections, renal infections, urogenital infections, neuro-meningeal infections, bone and joint infections, endocarditis, and treatment of skin infections caused by sensitive staphylococci and/or streptococci. cloxacillin is also indicated as preventive treatment of postoperative infections in neurosurgery.

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

athlone laboratories ltd - flucloxacillin sodium - capsule, hard - 500 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Мальта - англійська - Medicines Authority

novelgenix therapeutics limited 20, oliver business park, oliver road, park royal, london, nw10 7jb, united kingdom - flucloxacillin sodium - powder for oral solution - flucloxacillin sodium 250/5 milligram(s) - antibacterials for systemic use